Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Event

Axial Biotherapeutics Presents Preclinical Data on Microbiome-Derived Metabolites Associated with Autism Spectrum Disorder at the Society for Neuroscience 2019 Annual Meeting


Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that Dr. Torsten Madsen, acting Chief Medical Officer will be presenting preclinical data highlighting the strong association between bacteria-derived metabolites and autism spectrum disorder (ASD) at the Society for Neuroscience 2019 Annual Meeting on Saturday, October 19, 2019 in Chicago, IL.

"We are pleased to share these preclinical data, which further validate our scientific rationale and approach to treat ASD. Understanding the association between sustained levels of metabolites in systemic circulation and core and non-core behavioral symptoms associated with ASD is an important advance," said David Donabedian, Ph.D., and Co-founder and Chief Executive Officer of Axial Biotherapeutics. "Based on these data, we believe that our approach, i.e., that modulation of bacteria-derived metabolites may represent an important new treatment paradigm for the core and non-core symptoms of ASD."

Axial Biotherapeutics is currently investigating AB-2004, a first-in-class, therapeutic that removes metabolites in the gastrointestinal (GI) tract, in a Phase 1/2a safety and tolerability study.

Presentation Details:

Presentation Title: "Microbiome derived metabolites associated with autism spectrum disorder negatively impact multiple aspects of neuronal development and functionality"
Presenter: Torsten Madsen, MD, PhD
Poster Presentation: #030.08, Saturday, October 18, 2019, 1:00 PM CT

About Axial Biotherapeutics

Axial Biotherapeutics is a clinical stage biopharmaceutical company pioneering novel science focused on the interaction between the brain and the gut to mitigate the causes and symptoms of CNS and other gut-derived diseases. The Company has built a pipeline of novel small-molecules and live biotherapeutics with lead programs to address the significant unmet patient needs associated with Parkinson's Disease and Autism Spectrum Disorder.


These press releases may also interest you

at 11:08
"Operation Medic Bag" is a focused effort to respond to community expectations and improve PAYDAY 3. The initiative covers a range of sought-after features and improvements to gameplay, stability, matchmaking, content and enhanced features. The...

at 11:08
Sunwave Health, a leader in healthcare technology, proudly announces the launch of MARA, a patent-pending, innovative AI Agent designed to transform the landscape of behavioral health documentation. Since its launch on October 25, 2023, MARA has...

at 11:06
As...

at 11:05
LambdaTest, a leading cloud-based unified testing platform, announced the launch of The Phoenix Project, an Employee Resource Group (ERG) dedicated to supporting and promoting the success of its female employees. "LambdaTest is committed to...

at 11:05
We are pleased to announce the release of SecureSMX, a high-security RTOS for MCU-based products, such as IoT devices. It uses the hardware security features of Cortex-M-based processors to create hacker-proof, isolated partitions and to prevent...

at 11:05
Today, leading venue management software provider Clubspeed announced a partnership with Pedal Pub, a growing leader in the experiential tourism industry with more than 60 locations worldwide. "This is a strategic partnership that we are thrilled...



News published on and distributed by: